Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | FYN | P06241 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.63 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10389277 | 0.91 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4EMAPTMEN1POLB | |
| SCHEMBL10767950 | 0.89 | MAPT (0.69) | SMN1; SMN2KDM4EMAPTMEN1POLB | |
| SCHEMBL10389328 | 0.87 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EMAPTMEN1POLB | |
| SCHEMBL10694000 | 0.87 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EMAPTMEN1POLB | |
| SCHEMBL3476495 | 0.87 | MEN1 (0.71) | SMN1; SMN2KDM4EMAPTMEN1POLB | |
| SCHEMBL10771496 | 0.86 | FYN (0.65) | SMN1; SMN2KDM4EFYN | |
| SCHEMBL10389605 | 0.85 | MEN1 (0.69) | SMN1; SMN2KDM4EMAPTMEN1POLB | |
| SCHEMBL10389884 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM4EMAPTMEN1POLB | |
| SCHEMBL10695238 | 0.84 | MAPT (0.63) | SMN1; SMN2KDM4EMAPTMEN1POLB | |
| SCHEMBL10389949 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EMAPTMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025336-A | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-05-23 | — | — | CN | disclosed |
| CN-115087657-B | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-01-21 | — | — | CN | disclosed |
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-23 | — | — | US | disclosed |
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-23 | — | — | US | disclosed |
| EP-4077332-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021126779-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126779-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2010132286-A1 | ORALLY ADMINISTERED TABLET FORMULATION OF AN ANTIANXIOLYTIC COMPOUND | WYETH LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-1885367-A2 | METHOD FOR THE TREATMENT OF NOISE PHOBIA IN COMPANION ANIMALS | Wyeth (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006127574-A2 | METHOD FOR THE TREATMENT OF NOISE PHOBIA IN COMPANION ANIMALS | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| US-4892873-A | MUSCLE RELAXANTS, ANTIEPILEPTIC, AN XIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1990-01-09 | — | — | US | disclosed |
| US-4767765-A | ANXIOLYTIC OR ANTIEPILEPTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0232813-A2 | N6-substituted Adenosines | WARNER-LAMBERT COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0223974-A1 | N-Substituted-N-[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-phenyl]alkanamides, carbamates and ureas | AMERICAN CYANAMID COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
| US-4654343-A | USEFUL AS ANXIOLYTIC OR ANTIEPILEPTIC AGENTS AS WELL AS SEDATIVE-HYPNOTIC AND SKELETAL MUSCLE RELAXANT AGENTS | AMERICAN CYANAMID COMPANY (US) | 1987-03-31 | — | — | US | disclosed |
| US-4112095-A | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | LIN28A, DDX21, BMI1 | SMN1; SMN2 1080/4885KDM4E 219/4885FYN 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.